on OXURION (EBR:OXUR)
Oxurion to Acquire Majority Stake in Axiodis CRO
In a significant move, Oxurion NV announced a binding agreement to acquire 72% of Axiodis CRO's share capital. The transaction, valued at €468,000, positions the total company worth at €650,000. Completion is anticipated by June 2025, pending two conditions. Axiodis CRO, established in 2022, operates within clinical biometrics, offering comprehensive data management services in clinical trials through its Exagis software. This acquisition aligns with Oxurion's strategic shift towards integrating advanced clinical data capabilities, expanding their biopharmaceutical influence. Axiodis CRO forecasts increased revenue, aiming for over €2M by 2027, with plans for team expansion and technological development to enhance its market presence. The acquisition funding involves a shareholder loan from Oxurion, illustrating confidence despite financing challenges.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all OXURION news